Skip to main content
. 2015 Feb 24;5:8558. doi: 10.1038/srep08558

Table 1. Glutamate sensitivity of mutant AVR-14B GluCls.

  Glutamate Ivermectina
  EC50 (mM) nH Imax (μA) n Imax (μA) n
Wild-type 0.04 ± 0.01 1.7 ± 0.2 3.1 ± 0.3 4 2.4 ± 0.4 5
R95A b b 0.04 ± 0.02c 3 4.8 ± 1.9 3
S169A 27 ± 4*** 1.8 ± 0.2 4.3 ± 1.1 7    
Y199F b b 0.16 ± 0.04*** 6 0.7 ± 0.2 2
T245A 16 ± 0.8*** 2.0 ± 0.1 5.5 ± 0.8 7    
Y248F 0.07 ± 0.01 1.9 ± 0.2 4.3 ± 0.8 6    
R76N b b 0.19 ± 0.08c 6 3.6 ± 1.0 4
Q141R 6 ± 1** 0.9 ± 0.1** 1.1 ± 0.4** 5    
K219A 0.03 ± 0.01 2.1 ± 0.4 3.3 ± 0.5 3    
RN/QR/KA 34 ± 3*** 0.9 ± 0.1** 2.3 ± 0.3 5    
A197E b b 0.01 ± 0.01c 6 2.4 ± 0.7 4

Mean ± s.e.m. from n experiments.

a1 μM ivermectin was applied to oocytes at which glutamate gated little or no currents (and to WT-expressing oocytes), in order to verify functional expression of GluCls.

bCould not be determined.

cNot significantly different from zero (one-sample t test).

**P < 0.01,

***P < 0.001, compared to WT (unpaired Student's t test).